Pavlovic Z, Smotrich G, New E, Jahandideh S, Devine K, Imudia A
F S Rep. 2025; 5(4):369-377.
PMID: 39781068
PMC: 11705573.
DOI: 10.1016/j.xfre.2024.09.003.
Berkovitz-Shperling R, Samara N, Meir R, Dominsky O, Azam F, Feferkorn I
Arch Gynecol Obstet. 2024; 310(5):2297-2304.
PMID: 39302412
PMC: 11485447.
DOI: 10.1007/s00404-024-07740-7.
Jreij C, Halimeh R, Fadel D, Chamoun P, Nassar J, Saab W
J Reprod Infertil. 2024; 25(2):102-109.
PMID: 39157800
PMC: 11327421.
DOI: 10.18502/jri.v25i2.16005.
Forgiarini A, Contreras M, Bonta S, Maggi S, Espinel L
Clin Exp Reprod Med. 2024; 52(1):101-105.
PMID: 39039638
PMC: 11900659.
DOI: 10.5653/cerm.2024.06884.
Bedoschi G, Ingold C, Navarro P
Pathophysiology. 2024; 31(2):288-297.
PMID: 38921726
PMC: 11206524.
DOI: 10.3390/pathophysiology31020021.
The value of LH maximum level in predicting optimal oocyte yield following GnRH agonist trigger.
Lee W, Lin K, Hsieh Y, Kao T, Huang T, Chao K
Front Endocrinol (Lausanne). 2023; 14:1216584.
PMID: 37608795
PMC: 10441777.
DOI: 10.3389/fendo.2023.1216584.
Spontaneous and iatrogenic ovarian hyperstimulation syndrome in the absence of FSHR mutations: a case report of two unexpected cases.
Daolio J, Sperduti S, Casarini L, Falbo A, Materazzo C, Aguzzoli L
BMC Med Genomics. 2023; 16(1):45.
PMID: 36882810
PMC: 9990314.
DOI: 10.1186/s12920-023-01473-3.
Ovarian Hyperstimulation Syndrome (OHSS) requiring Intensive Care Unit (ICU) admission between 1996-2020 in England, Wales, and Northern Ireland.
Abbara A, Patel B, Parekh I, Garg A, Jayasena C, Comninos A
Front Endocrinol (Lausanne). 2023; 13:1060173.
PMID: 36589797
PMC: 9797661.
DOI: 10.3389/fendo.2022.1060173.
Severe Ovarian Hyperstimulation Syndrome in a Woman With Breast Cancer Under Letrozole Triggered With GnRH Agonist: A Case Report and Review of the Literature.
Iorio G, Rovetto M, Conforti A, Carbone L, Vallone R, Cariati F
Front Reprod Health. 2022; 3:704153.
PMID: 36303992
PMC: 9580822.
DOI: 10.3389/frph.2021.704153.
Use of gonadotropin-releasing hormone (GnRH) agonist trigger in fertility preservation for patients with inherited genetic disorders.
Merkison J, Malcom C, Decherney A
Front Endocrinol (Lausanne). 2022; 13:826419.
PMID: 36147559
PMC: 9486700.
DOI: 10.3389/fendo.2022.826419.
Agonist triggering in oocyte donation programs-Mini review.
Najdecki R, Michos G, Peitsidis N, Timotheou E, Chartomatsidou T, Kakanis S
Front Endocrinol (Lausanne). 2022; 13:838236.
PMID: 36093096
PMC: 9462512.
DOI: 10.3389/fendo.2022.838236.
Myostatin: a multifunctional role in human female reproduction and fertility - a short review.
Wang S, Fang L, Cong L, Chung J, Li T, Chan D
Reprod Biol Endocrinol. 2022; 20(1):96.
PMID: 35780124
PMC: 9250276.
DOI: 10.1186/s12958-022-00969-4.
Algorithm-based individualization methodology of the starting gonadotropin dose in IVF/ICSI and the freeze-all strategy prevent OHSS equally in normal responders: a systematic review and network meta-analysis of the evidence.
Marino A, Gullo S, Sammartano F, Volpes A, Allegra A
J Assist Reprod Genet. 2022; 39(7):1583-1601.
PMID: 35551563
PMC: 9365921.
DOI: 10.1007/s10815-022-02503-2.
Ovarian hyperstimulation syndrome: cardiac arrest with an unexpected outcome.
Gaughran J, Lyne T, Kopeika J, Hamilton J
BMJ Case Rep. 2021; 14(11).
PMID: 34799395
PMC: 8606776.
DOI: 10.1136/bcr-2021-246780.
To Compare the Effect of GnRH Agonist versus Human Chorionic Gonadotropin (HCG) Trigger on Clinical Pregnancy Rate in Intrauterine Insemination Cycle.
Sharma R, Meena I
J Hum Reprod Sci. 2021; 14(3):267-272.
PMID: 34759616
PMC: 8527070.
DOI: 10.4103/jhrs.JHRS_100_20.
Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome?.
Rubenfeld E, Dahan M
Obstet Gynecol Sci. 2021; 64(4):345-352.
PMID: 34102744
PMC: 8290150.
DOI: 10.5468/ogs.21067.
Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.
Christ J, Herndon C, Yu B
J Assist Reprod Genet. 2021; 38(3):751-756.
PMID: 33471229
PMC: 7910346.
DOI: 10.1007/s10815-020-02051-7.
Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
Castillo J, Haahr T, Martinez-Moya M, Humaidan P
Ups J Med Sci. 2020; 125(2):131-137.
PMID: 32366146
PMC: 7721056.
DOI: 10.1080/03009734.2020.1736696.
Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle.
Singh N, Dogra Y, Saini M, Govindarajan M
BMJ Case Rep. 2020; 13(1).
PMID: 31988058
PMC: 7035818.
DOI: 10.1136/bcr-2019-233379.
A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL.
Deng L, Li X, Ye D, Blockeel C, Zhou X, Chen S
Curr Med Sci. 2019; 39(2):278-284.
PMID: 31016522
DOI: 10.1007/s11596-019-2031-5.